Pharma Dynamics GmbH - Søgeresultater

Den Europæiske Union - dansk - EMA (European Medicines Agency)

clopidogrel acino pharma gmbh

acino pharma gmbh - clopidogrel - peripheral vascular diseases; stroke; myocardial infarction - antitrombotiske midler - clopidogrel er indiceret hos voksne til forebyggelse af atherothrombotic begivenheder i:patienter med myokardieinfarkt (fra få dage, indtil der er mindre end 35 dage), iskæmisk slagtilfælde (fra 7 dage indtil mindre end 6 måneder) eller etableret perifer arteriel sygdom. for yderligere oplysninger henvises der til afsnit 5.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

clopidogrel taw pharma (previously clopidogrel mylan)

taw pharma (ireland) limited - clopidogrelhydrochlorid - peripheral vascular diseases; stroke; myocardial infarction; acute coronary syndrome - antitrombotiske midler - , , , , secondary prevention of atherothrombotic events, , clopidogrel is indicated in: , - adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. , - adult patients suffering from acute coronary syndrome:, - non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). , - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy. , , in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is), clopidogrel in combination with asa is indicated in:, - adult patients with moderate to high-risk tia (abcd2 score ≥4) or minor is (nihss ≤3) within 24 hours of either the tia or is event. , , prevention of atherothrombotic and thromboembolic events in atrial fibrillation, in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. , , for further information please refer to section 5. , , ,.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

clopidogrel teva pharma b.v.

teva pharma b.v. - clopidogrel (as hydrobromide) - peripheral vascular diseases; acute coronary syndrome; myocardial infarction; stroke - antitrombotiske midler - forebyggelse af atherothrombotic eventsclopidogrel er angivet i:voksne patienter med myokardieinfarkt (fra få dage, indtil der er mindre end 35 dage), iskæmisk slagtilfælde (fra 7 dage indtil mindre end 6 måneder) eller etableret perifer arteriel sygdom;voksne patienter, der lider af akut koronar syndrom: non-st-segment elevation akut koronar syndrom (ustabil angina pectoris eller non-q-tak myokardieinfarkt), herunder patienter, der gennemgår en stent placering efter perkutan koronar intervention, i kombination med acetylsalicylsyre (asa);st-segment elevation akut myokardieinfarkt, i kombination med asa i medicinsk behandlede patienter, der er berettiget til trombolytisk terapi. forebyggelse af atherothrombotic og tromboemboliske hændelser i atrial fibrillationin voksne patienter med atrieflimren, der har mindst en risikofaktor for vaskulære hændelser, er ikke egnede til behandling med vitamin-k-antagonister (vka), og som har en lav risiko for blødning, clopidogrel er indiceret i kombination med asa til forebyggelse af atherothrombotic og tromboemboliske hændelser, herunder slagtilfælde.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

rivastigmine 1 a pharma

1 a pharma gmbh - rivastigmin - alzheimer disease; dementia; parkinson disease - psychoanaleptics, - symptomatisk behandling af mild til moderat alvorlig alzheimers demens. symptomatisk behandling af mild til moderat svær demens hos patienter med idiopatisk parkinsons sygdom.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

pioglitazone teva pharma

teva pharma b.v. - pioglitazonhydrochlorid - diabetes mellitus, type 2 - narkotika anvendt i diabetes - pioglitazone is indicated in the treatment of type-2 diabetes mellitus as monotherapy: , in adult patients (particularly overweight patients) inadequately controlled by diet and exercise for whom metformin is inappropriate because of contraindications or intolerance. , pioglitazone is also indicated for combination with insulin in type 2 diabetes mellitus adult patients with insufficient glycaemic control on insulin for whom metformin is inappropriate because of contraindications or intolerance. efter initiering af behandling med pioglitazon, patienter bør revurderes efter 3 til 6 måneder for at vurdere tilstrækkeligheden af respons på behandlingen (e. reduktion i hba1c). hos patienter, der undlader at vise et passende svar, pioglitazon bør seponeres. i lyset af potentielle risici med langvarig terapi, ordinerende læger bør bekræftes ved en efterfølgende rutinemæssige vurderinger, der har gavn af pioglitazon er fastholdt.